Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1815 in healthy volunteers, psoriasis, and atopic dermatitis
NCT03733353Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP1815 in psoriasis and atopic dermatitis (AD) (10 cohorts), sponsored by Evelo Biosciences. Primary endpoints: Safety and tolerability measured through Adverse Events, Safety and tolerability measured through lab measurements and 2 more. Started Nov 2018; status: completed.
02
Drugs
EDP1815
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03733353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733353.